

Ten-Year Trends in Potentially Inappropriate Sedative-Hypnotics and Pain Medication Use among Medicare Part D Beneficiaries

Mirchandani K¹, Sharma M¹, Aparasu RR²

¹Complete HEOR Solutions (CHEORS), Chalfont, PA, USA, ²University of Houston College of Pharmacy, Houston

KEY POINTS

Over the past decade (2013–2022),

- The use of potentially inappropriate medications, such as antipsychotics, has shown a modest decline
- utilization of skeletal muscle relaxants for pain management has increased

References

- Tian F, Chen Z, Zeng Y, Feng Q, Chen X. Prevalence of use of potentially inappropriate medications among older adults worldwide: a systematic review and meta-analysis. JAMA network open. 2023 Aug 1;6(8):e2326910.
- 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults Journal of the American Geriatrics Society. 2023 Jul;71(7):2052-81.
- Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC geriatrics. 2019 Dec;19:1-8.
- Clark CM, Shaver AL, Aurelio LA, Feuerstein S, Wahler Jr RG, Daly CJ, Jacobs DM. Potentially inappropriate medications are associated with increased healthcare utilization and costs. Journal of the American Geriatrics Society. 2020 Nov;68(11):2542-50.
- Borrelli EP. Assessing the prevalence of Beers medication utilization in the Medicare Part D population in 2020. Journal of the American Geriatrics Society. 2024 Sep;72(9):2800-6

For any questions please email: manvi.sharma@cheors.com



CONFLICT OF INTEREST

No funding was received from any external organization The authors report no other conflicts of interest in this work

BACKGROUND

- o Potentially inappropriate medications (PIMs) are defined as medicines that pose more risks than benefits¹
- o American Geriatric Society (AGS) Beer Criteria® 2023 lists PIMs that should be avoided by older adults with certain diseases or conditions²
- Obespite growing evidence of poor outcomes with PIM use, these medications continue to be prescribed to older adults in the United States $(US)^{3-5}$

OBJECTIVES

 To describe the multi-year utilization trends of PIMs among Medicare Part D beneficiaries aged ≥ 65 in the US

METHODS


- Study Design: Retrospective, cross-sectional study
- O Data Source: 2013-2022 Centers for Medicare and Medicaid Services Medicare Provider Utilization and Payment Data: Part D Prescriber public use files

5003

- Study Population: Medicare Part D beneficiaries aged ≥ 65 in the US
- O Potentially Inappropriate Medications: Sedative Hypnotics: Atypical antipsychotics (AAPs), Z-drugs, Benzodiazepines & Pain Medications: Oral Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Meperidine, Skeletal muscle relaxants
- Statistical Analysis: Descriptive statistics, i.e., number and percentage of beneficiaries and prescribers utilizing/prescribing PIMs, were reported


RESULTS

Figure 1: Percentage of beneficiaries with at least one claim for sedative-hypnotics and pain medications between 2013-2022



- The number of Medicare beneficiaries with Part D claims was 28.84 million in 2013 and 43.09 million in 2022
- Ouring the ten-year study period, Part D claims for sedative-hypnotics and pain medications were 7.28 million and 10.18 million, respectively
- There was a slight decrease in the beneficiaries utilizing antipsychotics (1.45 million (5.04%) to 2.03 million (4.72%)), benzodiazepines (5.51 million (19.13%) to 5.39 million (12.51%)), Z-drugs (1.91 million (6.62%) to 1.36 million (3.17%)), meperidine (10,784 (0.04%) to 4,449 (0.01%) (Refer to Figure 1)

Figure 2: Percentage of prescribers who prescribed inappropriate sedative-hypnotics and pain medications between 2013-2022



- There was an increase in the beneficiaries using NSAIDs (6.90 million (23.90%) to 10.52 million (24.40%)) and skeletal muscle relaxants (1.30 million (4.52%) to 2.14 million (4.96%))
- o Total number of prescribers was 1.05 million in 2013 and 1.33 million in 2022 - Antipsychotics prescribers increased - 137,868 (13.14%) in 2013 and 166,941 (12.53%) in 2022. Benzodiazepines prescribers increased - 236,339 (22.52%) in 2013 and 240,607 (18.06%) in 2022
- NSAID prescribers increased from 240,352 (22.91%) to 319,511 (23.98%), while skeletal muscle relaxant prescribers increased from 127,567 (12.16%) to 161,755 (12.14%) (Refer to Figure 2)

CONCLUSIONS

 Utilization of selected PIMs, such as antipsychotics, slightly declined, while NSAIDs and skeletal muscle relaxants increased during study period

LIMITATION

 The dataset captures only adjudicated prescription claims, excluding cash transactions and over-the-counter (OTC) purchases